Tandon R. Bridging the efficacy-effectiveness gap in the antipsychotic treatment of schizophrenia: back to the basics. J Clin Psychiatry. 2014;75(11):e1321-2. DOI: 10.4088/JCP.14com09595. PubMed PMID: 25470099.
Maillard AM, Ruef A, Pizzagalli F, Migliavacca E, Hippolyte L, Adaszewski S, et al. The 16p11.2 locus modulates brain structures common to autism, schizophrenia and obesity. Mol Psychiatry. 2015;20(1):140-7. DOI: 10.1038/mp.2014.145. PubMed PMID: 25421402.
Carbon M, Correll CU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. 2014;19 Suppl 1:38-52; quiz 35-7, 53. DOI: 10.1017/S1092852914000601. PubMed PMID: 25403863.
Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. Bmc Psychiatry. 2010;10:2. DOI: 10.1186/1471-244X-10-2. PubMed PMID: 20059765; PubMed Central PMCID: PMC2817695.
Dassa D, Boyer L, Benoit M, Bourcet S, Raymondet P, Bottai T. Factors associated with medication non-adherence in patients suffering from schizophrenia: a cross-sectional study in a universal coverage health-care system. Aust N Z J Psychiatry. 2010;44(10):921-8. DOI: 10.3109/00048674.2010.493503. PubMed PMID: 20932206.